A novel electrochemical nanobiosensor for the ultrasensitive and specific detection of femtomolar-level gastric cancer biomarker miRNA-106a

Nanomaterials in electrochemical nanobiosensors of miRNAs

Nanomaterial-based biosensors have received significant attention owing to their unique properties, especially enhanced sensitivity. Recent advancements in biomedical diagnosis have highlighted the role of microRNAs (miRNAs) as sensitive prognostic and diagnostic biomarkers for various diseases. Current diagnostics methods, however, need further improvements with regards to their sensitivity, mainly due to the low concentration levels of miRNAs in the body. The low limit of detection of nanomaterial-based biosensors has turned them into powerful tools for detecting and quantifying these biomarkers. Herein, we assemble an overview of recent developments in the application of different nanomaterials and nanostructures as miRNA electrochemical biosensing platforms, along with their pros and cons. The techniques are categorized based on the nanomaterial used.

Advances in Diagnostic Tools and Therapeutic Approaches for Gliomas: A Comprehensive Review

Gliomas, a prevalent category of primary malignant brain tumors, pose formidable clinical challenges due to their invasive nature and limited treatment options. The current therapeutic landscape for gliomas is constrained by a "one-size-fits-all" paradigm, significantly restricting treatment efficacy. Despite the implementation of multimodal therapeutic strategies, survival rates remain disheartening. The conventional treatment approach, involving surgical resection, radiation, and chemotherapy, grapples with substantial limitations, particularly in addressing the invasive nature of gliomas. Conventional diagnostic tools, including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET), play pivotal roles in outlining tumor characteristics. However, they face limitations, such as poor biological specificity and challenges in distinguishing active tumor regions. The ongoing development of diagnostic tools and therapeutic approaches represents a multifaceted and promising frontier in the battle against this challenging brain tumor. The aim of this comprehensive review is to address recent advances in diagnostic tools and therapeutic approaches for gliomas. These innovations aim to minimize invasiveness while enabling the precise, multimodal targeting of localized gliomas. Researchers are actively developing new diagnostic tools, such as colorimetric techniques, electrochemical biosensors, optical coherence tomography, reflectometric interference spectroscopy, surface-enhanced Raman spectroscopy, and optical biosensors. These tools aim to regulate tumor progression and develop precise treatment methods for gliomas. Recent technological advancements, coupled with bioelectronic sensors, open avenues for new therapeutic modalities, minimizing invasiveness and enabling multimodal targeting with unprecedented precision. The next generation of multimodal therapeutic strategies holds potential for precision medicine, aiding the early detection and effective management of solid brain tumors. These innovations offer promise in adopting precision medicine methodologies, enabling early disease detection, and improving solid brain tumor management. This review comprehensively recognizes the critical role of pioneering therapeutic interventions, holding significant potential to revolutionize brain tumor therapeutics.

Overview of miR-106a Regulatory Roles: from Cancer to Aging

MicroRNAs (miRNAs) comprise a class of non-coding RNA with extensive regulatory functions within cells. MiR-106a is recognized for its super-regulatory roles in vital processes. Hence, the analysis of its expression in association with diseases has attracted considerable attention for molecular diagnosis and drug development. Numerous studies have investigated miR-106 target genes and shown that this miRNA regulates the expression of some critical cell cycle and apoptosis factors, suggesting miR-106a as an ideal diagnostic and prognostic biomarker with therapeutic potential. Furthermore, the reported correlation between miR-106a expression level and cancer drug resistance has demonstrated the complexity of its functions within different tissues. In this study, we have conducted a comprehensive review on the expression levels of miR-106a in various cancers and other diseases, emphasizing its target genes. The promising findings surrounding miR-106a suggest its potential as a valuable biomolecule. However, further validation assessments and overcoming existing limitations are crucial steps before its clinical implementation can be realized.

Recent advancements in biosensor designs toward the detection of intestine cancer miRNA biomarkers

Cancer diagnosis and treatment have been of broad interest among scientists in the last decades due to the high death rate, widespread occurrence, and recurrence after treatment. The survival rate of cancer patients depends greatly on early detection and appropriate treatments. Therefore developing new technologies applicable to sensitive and specific methods of cancer detection is an inevitable task for cancer researchers. Abnormal miRNA expression is contributed to severe diseases such as cancers and since their expression level and type differ strictly during carcinogenesis and later metastasis and treatments, the improved detection accuracy of these miRNAs would undoubtedly lead to early diagnosis, prognosis, and targeted therapy. Biosensors are accurate and straightforward analytical devices that have had practical applications especially in the last decade. Their domain is still growing through a combination of attractive nanomaterials and amplification methods, leading to innovative biosensing platforms for the efficient detection of miRNAs as diagnostic and prognostic biomarkers. In this review, we will provide the recent developments in biosensors to detect intestine cancer miRNA biomarkers and also discuss the challenges and outcomings of this field.

Magnetite-Based Biosensors and Molecular Logic Gates: From Magnetite Synthesis to Application

In the last few decades, point-of-care (POC) sensors have become increasingly important in the detection of various targets for the early diagnostics and treatment of diseases. Diverse nanomaterials are used as building blocks for the development of smart biosensors and magnetite nanoparticles (MNPs) are among them. The intrinsic properties of MNPs, such as their large surface area, chemical stability, ease of functionalization, high saturation magnetization, and more, mean they have great potential for use in biosensors. Moreover, the unique characteristics of MNPs, such as their response to external magnetic fields, allow them to be easily manipulated (concentrated and redispersed) in fluidic media. As they are functionalized with biomolecules, MNPs bear high sensitivity and selectivity towards the detection of target biomolecules, which means they are advantageous in biosensor development and lead to a more sensitive, rapid, and accurate identification and quantification of target analytes. Due to the abovementioned properties of functionalized MNPs and their unique magnetic characteristics, they could be employed in the creation of new POC devices, molecular logic gates, and new biomolecular-based biocomputing interfaces, which would build on new ideas and principles. The current review outlines the synthesis, surface coverage, and functionalization of MNPs, as well as recent advancements in magnetite-based biosensors for POC diagnostics and some perspectives in molecular logic, and it also contains some of our own results regarding the topic, which include synthetic MNPs, their application for sample preparation, and the design of fluorescent-based molecular logic gates.

MicroRNA biosensors for detection of gastrointestinal cancer

Gastrointestinal (GI) cancers are one of the most common causes of cancer-related mortality. The discovery of microRNAs (miRs) and their unique role in cancer and other diseases has prompted the development of highly sensitive molecular diagnostic tools using nanomaterials as sensitive and specific biosensors. Among these, electrochemical biosensors, which are based on a simple and inexpensive design, make them desirable in clinical applications as well as a mass-produced point-of-care device. We review miR-based electrochemical biosensors in GI cancer and examine the use of nanoparticles in the evolving development of miR-based biosensors. Among these, a number of approaches including redox labeled probes, catalysts, redox intercalating agents and free redox indicators are highlighted for use in electrochemical biosensor technology.

Evaluation of probe-based ultra-sensitive detection of miRNA using a single-molecule fluorescence imaging method: miR-126 used as the model

This study proposed a new detection method of miRNA based on single-molecule fluorescence imaging, a method that has been successfully developed to measure the light signal of individual molecules labeled with proper fluorophores. We designed probes 1 and 2 to be labeled with Cy5 dye and BHQ2 quencher at the 3'terminals, respectively. Probe 1 consisted of two parts, the longer part complementary to miR-126 and the shorter part complementary to probe 2. After hybridization, miR-126 bound to probe 1 by replacing probe 2 and assembled into a double-stranded DNA with probe 1. The abundance of miR-126 was quantified by detecting image spots of Cy5 dye molecules from probe 1/miR-126 complexes. MiR-126 single-molecule imaging method showed high specificity and sensitivity for miR-126 with a detection limit of 50 fM. This method has good selectivity for miR-126 detection with 2.1-fold, 8.8-fold, and 26.9-41.3-fold higher than those of single-base mismatched miR-126, three-base mismatched miR-126 and non-complementary miRNAs (miR-221, miR-16, miR-143 and miR-141). The method to detect miR-126 was validated in breast cancer cell lines. Our single-molecule miRNA imaging showed high specificity and sensitivity for miRNAs. By changing the base pair sequence of the designed probes, our method would be able to detect different miRNAs.

Electrochemical Biosensors in the Diagnosis of Acute and Chronic Leukemias

Until now, morphological assessment with an optical or electronic microscope, fluorescence in situ hybridization, DNA sequencing, flow cytometry, polymerase chain reactions, and immunohistochemistry have been employed for leukemia identification. Nevertheless, despite their numerous different vantages, it is difficult to recognize leukemic cells correctly. Recently, the electrochemical evaluation with a nano-sensing interface seems an attractive alternative. Electrochemical biosensors measure the modification in the electrical characteristics of the nano-sensing interface, which is modified by the contact between a biological recognition element and the analyte objective. The implementation of nanosensors is founded not on single nanomaterials but rather on compilating these components efficiently. Biosensors able to identify the molecules of deoxyribonucleic acid are defined as DNA biosensors. Our review aimed to evaluate the literature on the possible use of electrochemical biosensors for identifying hematological neoplasms such as acute promyelocytic leukemia, acute lymphoblastic leukemia, and chronic myeloid leukemia. In particular, we focus our attention on using DNA electrochemical biosensors to evaluate leukemias.

Diagnosis of Pancreatic Cancer Using miRNA30e Biosensor

This work describes miRNA-based electrochemical biosensor for detection of miRNA30e, a pancreatic cancer biomarker. The screen-printed gold electrode was functionalized using cysteine hydrochloride followed by immobilization of synthesized colloidal gold nanorods (10-12 nm diameter and 25-65 nm length). The gold nanorods modified electrode surface was amino functionalized for covalent attachment of single-stranded DNA probe against miRNA30e (miR30e). This platform was utilized for electrochemical measurements and response analysis of target miRNA30e. Electrochemical impedance spectroscopic measurements showed very poor sensitivity (13.51 Ω/µg/mL/cm²) using charge transfer resistance calibration plots. Cyclic voltammetry and differential pulse voltammetry-based miR30e quantification showed decreasing current response with increasing concentration of miR30e with detection range of 0.1 fg/mL-0.1 µg/mL (14.9 aM-14.9 nM). The sensitivity of DPV sensing (104.4 µA/µg/mL/cm²) was found to be 1.3 times higher than that of CV-based quantification (79.6 µA/µg/mL/cm²). miRNA-based biosensors have the potential of replacing current invasive, time consuming and technically difficult diagnostic procedures. Furthermore, the lower limit of detection of 14.9 aM miRNA30e makes it a promising tool for detection of cancer at early stages and hence increasing survival rate.

Application of nanotechnology in the early diagnosis and comprehensive treatment of gastrointestinal cancer

Gastrointestinal cancer (GIC) is a common malignant tumour of the digestive system that seriously threatens human health. Due to the unique organ structure of the gastrointestinal tract, endoscopic and MRI diagnoses of GIC in the clinic share the problem of low sensitivity. The ineffectiveness of drugs and high recurrence rates in surgical and drug therapies are the main factors that impact the curative effect in GIC patients. Therefore, there is an urgent need to improve diagnostic accuracies and treatment efficiencies. Nanotechnology is widely used in the diagnosis and treatment of GIC by virtue of its unique size advantages and extensive modifiability. In the diagnosis and treatment of clinical GIC, surface-enhanced Raman scattering (SERS) nanoparticles, electrochemical nanobiosensors and magnetic nanoparticles, intraoperative imaging nanoparticles, drug delivery systems and other multifunctional nanoparticles have successfully improved the diagnosis and treatment of GIC. It is important to further improve the coordinated development of nanotechnology and GIC diagnosis and treatment. Herein, starting from the clinical diagnosis and treatment of GIC, this review summarizes which nanotechnologies have been applied in clinical diagnosis and treatment of GIC in recent years, and which cannot be applied in clinical practice. We also point out which challenges must be overcome by nanotechnology in the development of the clinical diagnosis and treatment of GIC and discuss how to quickly and safely combine the latest nanotechnology developed in the laboratory with clinical applications. Finally, we hope that this review can provide valuable reference information for researchers who are conducting cross-research on GIC and nanotechnology.

Engineered nanomedicines for augmenting the efficacy of colorectal cancer immunotherapy

Colorectal cancer (CRC) is one of the most devastating diseases worldwide. Immunotherapeutic agents for CRC treatment have shown limited efficacy due to the immunosuppressive tumor microenvironment (TME). In this context, various types of nanoparticles (NPs) have been used to reverse the immunosuppressive TME, potentiate the effect of immunotherapeutic agents and reduce their systemic side effects. Many advantages could be offered by NPs, related to drug-loading efficiency, particle size and others that can potentially aid the delivery of immunotherapeutic agents. The recent research on how nano-based immunotherapy can remodel the immunosuppressive TME of CRC and hence boost the antitumor immune response, as well as the challenges that face clinical translation of NPs and future perspectives, are summarized in this review article.

Multilayered Mesoporous Composite Nanostructures for Highly Sensitive Label-Free Quantification of Cardiac Troponin-I

Cardiac troponin-I (cTnI) is a well-known biomarker for the diagnosis and control of acute myocardial infarction in clinical practice. To improve the accuracy and reliability of cTnI electrochemical immunosensors, we propose a multilayer nanostructure consisting of Fe₃O₄-COOH labeled anti-cTnI monoclonal antibody (Fe₃O₄-COOH-Ab₁) and anti-cTnI polyclonal antibody (Ab₂) conjugated on Au-Ag nanoparticles (NPs) decorated on a metal–organic framework (Au-Ag@ZIF-67-Ab₂). In this design, Fe₃O₄-COOH was used for separation of cTnI in specimens and signal amplification, hierarchical porous ZIF-67 extremely enhanced the specific surface area, and Au-Ag NPs synergically promoted the conductivity and sensitivity. They were additionally employed as an immobilization platform to enhance antibody loading. Electron microscopy images indicated that Ag-Au NPs with an average diameter of 1.9 ± 0.5 nm were uniformly decorated on plate-like ZIF-67 particles (with average size of 690 nm) without any agglomeration. Several electrochemical assays were implemented to precisely evaluate the immunosensor performance. The square wave voltammetry technique exhibited the best performance with a sensitivity of 0.98 mA mL cm⁻² ng⁻¹ and a detection limit of 0.047 pg mL⁻¹ in the linear range of 0.04 to 8 ng mL⁻¹.

A ratiometric electrochemical DNA-biosensor for detection of miR-141

A sensitive biosensor for the detection of miR-141 has been constructed. The DNA-biosensor is prepared by first immobilizing the thiolated methylene blue-labeled hairpin capture probe (MB-HCP) on two-layer nanocomposite film graphene oxide-chitosan@ polyvinylpyrrolidone-gold nanourchin modified glassy carbon electrode. We used the hematoxylin as an electrochemical auxiliary indicator in the second stage to recognize DNA hybridization via the square wave voltammetry (SWV) responses that record the accumulated hematoxylin on electrode surfaces. The morphology and chemical composition of nanocomposite was characterized using TEM, FE-SEM, and FT-IR techniques. The preparation stages of the DNA-biosensor were screened by electrochemical impedance spectroscopy and cyclic voltammetry. The proposed DNA-biosensor can distinguish miR-141 from a non-complementary and mismatch sequence. A detection limit of 0.94 fM and a linear range of 2.0 -5.0 × 10⁵ fM were obtained using SWV for miR-141 detection. The working potential for methylene blue and hematoxylin was -0.28 and + 0.15 V vs. Ag/AgCl, respectively. The developed biosensor can be successfully used in the early detection of non-small cell lung cancer (NSCLC) by directly measuring miR-141 in human plasma samples. This novel DNA-biosensor is of promise in early sensitive clinical diagnosis of cancers with miR-141 as its biomarker.

Electrochemical immunosensor for determination of cardiac troponin I using two-dimensional metal-organic framework/Fe3O4-COOH nanosheet composites loaded with thionine and pCTAB/DES modified electrode

Cardiac troponin-I (CTnI) is one of the most popular biomarkers which can be utilized for the diagnosis and control of acute myocardial infarction in clinical practice. Here, a sandwich-type electrochemical immunosensor has been established using the zinc-based metal-organic framework/Fe₃O₄-COOH/thionine labeled anti-CTnI monoclonal antibody (Ab₁-Zn-MOF/Fe₃O₄-COOH/Thi) nanocomposite as signaling molecule and a polymer film of cetyltrimethylammonium bromide (pCTAB) in the presence of choline chloride-urea deep eutectic solvent (DES) and anti-CTnI polyclonal antibody (Ab₂) as immobilization substance of detecting surface. The porous ultrathin layers of Zn-MOF nanosheets successfully prepare a well-defined structure for Fe₃O₄-COOH electrocatalyst and Thi within a certain two dimensional (2D) regions, which enhances electrochemical reduction of Thi. The Ab₁-Zn-MOF/Fe₃O₄-COOH/Thi nanocomposites were introduced to CTnI in the specimen and on the surface of pCTAB/DES-Au-SPE quantitative determination of CTnI was achieved using differential pulse voltammetry after sandwiching the CTnI target between Ab₁-nanocomposite and Ab₂ which was encapsulated into the pCTAB/DES-Au-SPE. This immunosensor indicated the appropriate assay performance for CTnI with the detection range of 0.04 ng mL^-1 to 50 ng mL^-1 and the limit of detection of 0.0009 ng mL^-1. This study provides convenient plan for sensitive detection of bioanalytes and opens a path for the establishment of user-friendly and cost-effective device.

Simultaneous Detection of SARS-CoV-2 IgG/IgM Antibodies, Using Gold Nanoparticles-Based Lateral Flow Immunoassay

The novel coronavirus disease (COVID-19), known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), exhibits a strong human-to-human transmission infectivity and could cause acute respiratory infections. Therefore, simple and rapid serological testing is urgently needed to recognize positive cases. In this study, a point-of-care serological test based on lateral flow immunoassay (LFIA) was developed and its application for the simultaneous detection of IgM/IgG antibodies against SARS-CoV-2 was evaluated. The recombinant SARS-CoV-2 antigens were conjugated to the produced colloidal gold nanoparticles and used as the detection reagent. This test required only 10-15 minutes to achieve simultaneous qualitative detection of IgM/IgG antibodies specific to SARS-CoV-2 in 20 μL of serum or plasma samples. The clinical performance and reliability of the assay were evaluated by performing the test with 60 samples and comparing the results of these tests with those obtained via real-time polymerase chain reaction. The sensitivity and specificity of our assay were defined to be 90% and 96.6%, respectively. The presented LFIA was sufficiently sensitive and accurate to be used for the rapid diagnosis of coronavirus disease 2019 in laboratories or in patient care settings, particularly in emergency conditions, in which many samples require to be evaluated on time.

Electrochemiluminescence paper-based screen-printed electrode for HbA1c detection using two-dimensional zirconium metal-organic framework/Fe3O4 nanosheet composites decorated with Au nanoclusters

Glycated hemoglobin (HbA1c) is one of the most popular biomarkers which can be utilized for the diagnosis and control of diabetes in clinical practice. In this study, a sandwich paper-based electrochemiluminescence (ECL) biosensor has been developed using the zirconium metal-organic framework/Fe₃O₄(trimethyl chitosan)/gold nanocluster (Zr-MOF/Fe₃O₄(TMC)/AuNCs) nanocomposite as tracing tag to label anti-HbA1c monoclonal antibody and reduced graphene oxide (rGO) as immobilization platform of sensing element. The screen-printed electrodes (SPEs) were constructed and modified by sputtering a thick layer of gold on the paper substrate, followed by electrochemical reduction of aminophenylboronic acid (APBA)-functionalized GO to rGO/APBA, respectively. Different types of surface analysis methods were applied to characterize the Zr-MOF/Fe₃O₄(TMC)/AuNCs nanomaterials fabricated. Finally, antibody-labeled Zr-MOF/Fe₃O₄(TMC)/AuNCs nanocomposites were subjected to HbA1c in the sample and on the paper-based SPE. Quantitative measurement of HbA1c was performed using ECL and cyclic voltammetry (CV) over a potential range of - 0.2 to 1.7 V vs gold reference electrode with a sweep rate of 0.2 V.s^-1 in the presence of triethylamine as a co-reactant after sandwiching the HbA1c target between antibody and APBA on the sensing area. This immunosensor demonstrated the desirable assay performance for HbA1c with a wide response range from 2 to 18% and a low detection limit (0.072%). This new strategy provides an effective method for high-performance bioanalysis and opens avenues for the development of high-sensitive and user-friendly device. Graphical abstract.

Femtomolar determination of an ovarian cancer biomarker (miR-200a) in blood plasma using a label free electrochemical biosensor based on L-cysteine functionalized ZnS quantum dots

In the present study, a label-free electrochemical genosensor was designed based on ZnS quantum dots functionalized with l-cysteine (Cys-ZnS-QDs) to detect miR-200a, as a special ovarian cancer biomarker. The Cys-ZnS-QD genosensor was characterized by transmission electron microscopy (TEM), UV-Vis absorption and fluorescence methods. Cys-ZnS-QDs are electrodeposited on the glassy carbon electrode surface and act as a suitable substrate for immobilization of the DNA probe. The effective parameters in the preparation of the genosensor are optimized to improve its analytical performance. The analytical performance of the genosensor has been investigated using electrochemical impedance spectroscopy. Under optimal conditions, the linear range and the detection limit of miR-200a were found to be 1.0 × 10-14 to 1.0 × 10-6 M and 8.4 fM. In addition, the genosensor is used to detect the target complementary miRNA strand from a single-base mismatch miRNA strand. Finally, this label-free electrochemical biosensor was used to detect miR-200a in human plasma without using any amplification method.

Point-of-care cancer diagnostic devices: From academic research to clinical translation

Early and timely diagnosis of cancer plays a decisive role in appropriate treatment and improves clinical outcomes, improving public health. Significant advances in biosensor technologies are leading to the development of point-of-care (POC) diagnostics, making the testing process faster, easier, cost-effective, and suitable for on-site measurements. Moreover, the incorporation of various nanomaterials into the sensing platforms has yielded POC testing (POCT) platforms with enhanced sensitivity, cost-effectiveness and simplified detection schemes. POC cancer diagnostic devices provide promising platforms for cancer biomarker detection as compared to conventional in vitro diagnostics, which are time-consuming and require sophisticated instrumentation, centralized laboratories, and experienced operators. Current innovative approaches in POC technologies, including biosensors, smartphone interfaces, and lab-on-a-chip (LOC) devices are expected to quickly transform the healthcare landscape. However, only a few cancer POC devices (e.g. lateral flow platforms) have been translated from research laboratories to clinical care, likely due to challenges include sampling procedures, low levels of sensitivity and specificity in clinical samples, system integration and signal readout requirements. In this review, we emphasize recent advances in POC diagnostic devices for cancer biomarker detection and discuss the critical challenges which must be surmounted to facilitate their translation into clinical settings.

Electrochemical Biosensors for Detection of MicroRNA as a Cancer Biomarker: Pros and Cons

Cancer is the second most fatal disease in the world and an early diagnosis is important for a successful treatment. Thus, it is necessary to develop fast, sensitive, simple, and inexpensive analytical tools for cancer biomarker detection. MicroRNA (miRNA) is an RNA cancer biomarker where the expression level in body fluid is strongly correlated to cancer. Various biosensors involving the detection of miRNA for cancer diagnosis were developed. The present review offers a comprehensive overview of the recent developments in electrochemical biosensor for miRNA cancer marker detection from 2015 to 2020. The review focuses on the approaches to direct miRNA detection based on the electrochemical signal. It includes a RedOx-labeled probe with different designs, RedOx DNA-intercalating agents, various kinds of RedOx catalysts used to produce a signal response, and finally a free RedOx indicator. Furthermore, the advantages and drawbacks of these approaches are highlighted.

Point-of-care biosensors in medicine: a brief overview of our achievements in this field based on the conducted research in EMRI (endocrinology and metabolism research Institute of Tehran University of medical sciences) over the past fourteen years

The growing demand of diagnostic tools with enhanced analytical characteristics in term of sensitivity, selectivity, and low response time has encouraged researches to conduct their research towards development of point-of-care (POC) biosensors. POC diagnostic devices are powerful tools for detection, diagnosis, and monitoring of diseases at its initial stage. The above characteristics encouraged us to conduct active multidisciplinary and collaborative research oriented towards the design and development of POC sensing systems. Here, we present a brief overview of our recent achievement in the field of biomedical POC devices implemented in paper based microfluidic and screen printing electrodes and discuss the critical limitations that need to be surmounted to facilitate their translation into clinical practice in the future.

Label-free ultrasensitive detection of breast cancer miRNA-21 biomarker employing electrochemical nano-genosensor based on sandwiched AgNPs in PANI and N-doped graphene

MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs, shown to be expressed abnormally in many tumors and identified as predictive biomarkers for early diagnosis of several cancers including the breast. Therefore, the label-free and highly sensitive detection of miRNAs is of critical significance. In this work, a highly sensitive and label-free nano-genosensor is developed for the detection of miRNA-21, a known breast cancer biomarker, based on a specific architecture of nitrogen-doped functionalized graphene (NFG), silver nanoparticles (AgNPs), and polyaniline (PANI) that resulted in a remarkable effect on signal amplification. Following the successful functionalization of the nanocomposite and immobilization of the specific sequence of the aminated complementary oligonucleotide of miRNA-21, the detection was performed using differential pulse voltammetry (DPV). The oxidation peak current of the redox probe under optimal conditions was determined to monitor the event hybridization of miRNA-21 biomarker. Applying this highly sensitive and optimized nano-biosensor enabled detection of a wide dynamic range of 10 fM-10 µM with a sensitivity of 2.5 µA cm^-2 and a low detection limit of 0.2 fM. This nano-biosensor also demonstrated highly reproducible results in the analysis of blood samples, with recoveries between 94% and 107%, and could be used for early detection of breast cancer by direct detection of the miRNA-21 in real clinical samples without any need to sample preparation, RNA extraction and/or amplification.

Nano-biosensor based on reduced graphene oxide and gold nanoparticles, for detection of phenylketonuria-associated DNA mutation

Phenylketonuria (PKU)-associated DNA mutation in newborn children can be harmful to his health and early detection is the best way to inhibit consequences. A novel electrochemical nano-biosensor was developed for PKU detection, based on signal amplification using nanomaterials, e.g. gold nanoparticles (AuNPs) decorated on the reduced graphene oxide sheet on the screen-printed carbon electrode. The fabrication steps were checked by field emission scanning electron microscope imaging as well as cyclic voltammetry analysis. The specific alkanethiol single-stranded DNA probes were attached by self-assembly methodology on the AuNPs surface and Oracet blue was used as an intercalating electrochemical label. The results showed the detection limit of 21.3 fM and the dynamic range of 80-1200 fM. Moreover, the selectivity results represented a great specificity of the nano-biosensor for its specific target DNA oligo versus other non-specific sequences. The real sample simulation was performed successfully with almost no difference than a synthetic buffer solution environment.

Voltammetric determination of the Escherichia coli DNA using a screen-printed carbon electrode modified with polyaniline and gold nanoparticles

The authors describe an electrochemical assay for fast detection of Escherichia coli (E. coli). It is based on a dual signal amplification strategy and the use of a screen-printed carbon electrode (SPCE) whose surface was modified with a polyaniline (PANI) film and gold nanoparticles (AuNPs) via cyclic voltammetry (CV). In the next step, avidin was covalently immobilized on the PANI/AuNP composite on the SPCE surface. Subsequently, the biotinylated DNA capture probe was immobilized onto the PANI/AuNP/avidin-modified SPCE by biotin-avidin interaction. Then, DNA of E.coli, digoxigenin-labeled DNA detector probe and anti-digoxigenin-labeled horseradish peroxidase (HRP) were placed on the electrode. 3,3',5,5'-Tetramethylbenzidine (TMB) and H₂O₂ solution were added and the CV electrochemical signal was generated at a potential of -0.1 V (vs. Ag/AgCl) and a scan rate 50 mV.s^-1. The assay can detect 4 × 10⁶ to 4 CFU of E. coli without DNA amplification. The biosensor is highly specific over other pathogens including Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecalis, Staphylococcus haemolyticus and Pseudomonas aeruginosa. It can be concluded that this genosensor has an excellent potential for rapid and accurate diagnosis of E.coli inflicted infections. Graphical Abstract Schematic of an electrochemical E. coli genosensor based on sandwich assay on a polyaniline/gold nanoparticle-modified screen printed carbon electrode (SPCE). The biosensor can detect 4 × 10⁶ to 4 CFU of E. coli without DNA amplification.

Recent advances in carbon nanotube based electrochemical biosensors

There is an increasing need for rapid, low cost, reusable, reliable and sensitive detection systems for diagnosing infectious diseases, metabolic disorders, rapidly advancing cancers and detecting the presence of environmental pollutants. Most traditional methods are invasive, slow, expensive and laborious, requiring highly specialized instruments. Introduction of biosensors with nanomaterials as transducers of signals have helped in removing the disadvantages associated with traditional detectors. The properties of high mechanical strength, better electrical conductivity and ability to serve as efficient signal transducers make carbon nanotubes (CNTs) ideal material for biosensor applications among the gamut of nanomaterials. Further, CNTs with their high surface areas, easily functionalizable surfaces for receptor immobilization are gaining importance in the construction of biosensors. The expanding field of CNTs bridges the physical sciences with biology, as chemical methods are employed to develop novel tools and platforms for understanding biological systems, in disease diagnosis and treatment. This review presents recent advances in surface functionalization of CNTs necessary for immobilization of enzymes and antibodies for biosensor applications and the methodologies used for the detection of a number of chemical and biological species. The review ends with a speculation on future prospects for CNTs in biology and medicine.

The promising potentials of capped gold nanoparticles for drug delivery systems

Fabrication and characterisation of gold nanoparticles (GNPs) through reducing agents and different capped agents are one of their most attractive applications in biomedicine. GNPs are coated using various agents such as carbohydrate, amino acids, peptides and proteins. These capped gold nanoparticles (C-GNPs) are applied for wide different applications including drug delivery in the recent decade and potential treatment and diagnosis in drug delivery systems (DDS). Recent studies have shown that these novel compounds and conjugated-nanoparticles drugs play a key role for the promising cure of high-risk refractory diseases. In addition, it seems that these compounds have a capability for potential treatment of certain cancers. In this review, a well-defined description of C-GNPs and the application of these nanoparticles are discussed. Our study revealed that C-GNPs with anticancer drugs or new compounds could be potentially applied for biomedical usage especially in cancer therapy.

Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker

Objective

To evaluate miR-25 expression in serum of gastric cancer (GC) patients and whether it can be a potential biomarker for GC diagnosis.

Methods

Forty one pathology confirmed GC patients and 41 healthy controls were included in this study. 10 mL peripheral venous blood were collected from GC patients and healthy controls. miR-25 relative expression and CA19-9 level in serum of GC patients and healthy controls were measured by real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) and enzyme linked immunosorbent assay (ELISA), respectively. The diagnostic sensitivity, specificity and receiver operating characteristic (ROC) curve of serum miR-25 and CA19-9 were calculated by STATA11.0 software.

Results

The relative expression of miR-25 was 0.47±0.53 and 0.05±0.36 in serum of GC patients and healthy controls respectively with significant statistical difference (P<0.05). The serum level of CA19-9 for GC patients and healthy controls were 11.91±6.17 U/mL and 7.40±3.97 U/mL, indicating GC patients were much higher than those of healthy controls (P<0.05). The diagnostic sensitivity and specificity were 78.05% and 60.98% with the cut-off value of 0.32 for serum miR-25. Under this cut-off value, the area under the ROC curve was 0.75. For serum CA19-9, the diagnostic sensitivity and specificity were 70.73% and 56.10% with the cut-off value of 9.22 U/mL. Under this cut-off value, the area under the ROC curve was 0.73 with the 95% confidence interval of 0.62-0.84. Positive correlation was found between serum miR-25 relative expression and CA19-9 concentration of GC patients (r=0.75, P<0.05).

Conclusion

According to our present study, serum miR-25 was elevated in GC patients which may serve as a diagnostic biomarker for GC.

Early detection of Alzheimer's disease using a biosensor based on electrochemically-reduced graphene oxide and gold nanowires for the quantification of serum microRNA-137

Serum miR-137 is quantified for the early detection of Alzheimer's disease using a electrochemically reduced graphene oxide and gold nanowire modified electrode.